INTRODUCTION
The historical approach to prostate cancer (PCa) detection is a 10-to 12-core transrectal ultrasound (TRUS)-guided systematic biopsy (SB). However, patients who have a prior negative SB and persistent suspicion of PCa represent a clinical dilemma for urologists. Since the introduction of multiparametric magnetic resonance imaging (mpMRI) and magnetic resonance (MR)/ultrasound (US) fusion biopsy (FB), the diagnostic yield for PCa with a Gleason score (GS) 3 1 4 has been found to be higher in comparison with SB alone, particularly for patients who have previously undergone biopsy. 1, 2 FB technology is rapidly being adopted at many centers. 3, 4 According to a consensus statement by the American Urological Association and the Society of Abdominal Radiology, the use of mpMRI after a prior negative biopsy is supported by the current literature, and patients with a Prostate Imaging Reporting and Data System (PI-RADS) suspicion score of 3 to 5 warrant a biopsy. 5 The detection rate for PCa with a GS 3 1 4 is highly dependent on the PI-RADS score. 6 Although lesions with a PI-RADS score of 3 are generally considered abnormal, 7 some groups have reported that clinically significant cancer is infrequently detected when lesions with a PI-RADS score of 3 are biopsied. 8 Currently, it is unclear whether all patients with a lesion with a PI-RADS score of 3 to 5 should undergo biopsy or whether some patients can be safely spared an unnecessary biopsy despite abnormal mpMRI findings.
Several mpMRI-based nomograms have been previously developed for use in PCa patients on active surveillance. [9] [10] [11] Another nomogram was recently developed for use in patients who are naive to prostate biopsy. 12 Currently, validated nomograms for use in the prior negative biopsy population, particularly those that incorporate PI-RADS version 2, are much needed. 13 In the current study, we used clinical and mpMRI variables to develop and validate a nomogram for predicting negative FB results that can be used to reduce the number of unnecessary biopsies in this specific population of patients.
MATERIALS AND METHODS
Two academic centers were included in this institutional review board-approved retrospective study. A nomogram was developed with 285 consecutive patients with at least 1 prior negative biopsy session who underwent FB for abnormal mpMRI findings (ie, a PI-RADS score of [3] [4] [5] at the University of Rochester Medical Center (URMC) from December 2014 to December 2016, or at the University of Alabama at Birmingham (UAB) from February 2014 to February 2017. The indication for performing mpMRI at both institutions was continued clinical suspicion for clinically significant PCa in patients with at least 1 prior negative biopsy. Patients were excluded if they were biopsy-naive or had an existing PCa diagnosis. Biopsy cores were graded according to the most recent 2014 International Society of Urological Pathology recommendations. 14 The study was approved by the institutional review board at each institution.
Magnetic Resonance Imaging (MRI) Acquisition and FB
At URMC and UAB, all prostate mpMRI examinations were performed with 3-T MRI scanners without the use of an endorectal coil as previously described. 15, 16 At both institutions, postimage processing of contrast kinetics and 3-dimensional segmentation of MRI lesions and whole prostate volumes was performed with computer assistance with DynaCAD software (InVivo Corp, Gainesville, Florida). MRI interpretation was performed by 2 radiologists at URMC and by a multidisciplinary consensus conference with fellowship-trained radiologists and urologic oncologists specializing in prostate MRI at UAB; all had more than 3 years of experience in interpreting prostate mpMRI. At URMC, only PI-RADS version 2 was used. At UAB, PI-RADS version 2 was adopted after its introduction in 2015, whereas PI-RADS version 1 was used before that. All MR/US FB procedures were performed by 5 urologists and 2 urologic oncologists at URMC and UAB, respectively, and they consisted of targeted biopsy (TB) and concurrent 12-to 14-core SB (TB1SB) with a commercially available, software-based FB device (UroNav; InVivo Corp). At least 2 TB cores were obtained for each visible region of interest on mpMRI as previously recommended. 17 The lesion with the highest PI-RADS score was considered the index lesion. Nonindex lesions assigned a PI-RADS score of 1 to 2 did not undergo TB because these lesions rarely harbor significant PCa.
Statistical Analysis
Clinical and mpMRI variables were collected and included the following: age, race, body mass index, digital rectal examination findings, number of prior negative biopsies, prostate-specific antigen (PSA), prostate-specific antigen density (PSAD) as a continuous variable, PSAD as a categorical variable (with a cutoff of 0.15), MRIderived prostate volume, PI-RADS score, mpMRI index lesion size, and index lesion location (anterior vs posterior). The MRI-derived prostate volume was based on 3-dimensional segmentation of the prostate gland on postimage processing software, and PSAD was calculated with the MRI-estimated prostate volume. Multicollinearity was assessed for continuous variables with a Pearson correlation matrix (Supporting Table 1 Multiple logistic regression analysis was performed to generate prediction models with age, PSA, prostate volume, and PI-RADS score. To determine whether using PSAD versus PSA and prostate volume (as separate covariates) generated more accurate models, multivariate logistic regression was performed with backward selection with a P value cutoff of .2. Logistic regression models were constructed at each individual institution and were subsequently externally validated at the other; these models were named URMC 345 and UAB 345. The final logistic regression model was constructed with a combined URMC-UAB data set to maximize its generalizability for future clinical use; this model was named URMC1UAB 345. The predictive accuracy of the regression models was assessed, with a receiver operating characteristic curve used to calculate the area under the curve (AUC).
Statistical analysis was performed with SAS 9.4 (SAS Institute, Inc, Cary, North Carolina). The significance level was set at 0.05. Calibration and decision analysis curves were generated with R package libraries rms and DecisionCurve, respectively.
RESULTS
A total of 285 patients at URMC and UAB with a prior negative biopsy met the inclusion criteria for this study ( Table 1 ). The median age was 66 years (interquartile range, 61-70 years). The median PSA values at URMC and UAB were 9.5 (interquartile range, 6.9-15.0) and 8.0 (interquartile range, 5.5-12.0), respectively. At URMC and UAB, 65 of 142 patients (45.8%) and 67 of 143 patients (46.7%), respectively, had benign TB1SB pathology. The median surgeon case volumes at URMC and UAB were 14 (range, 7-39) and 72 (range, 52-91), respectively, during the study period.
In the univariate analysis, race, body mass index, digital rectal examination findings, and number of prior negative biopsies were poorly predictive of benign pathology, regardless of the institution (Supporting Table 2 [see online supporting information]). Although the mpMRI index lesion size was predictive of benign pathology, it was highly collinear with PSA, as demonstrated by Pearson correlation coefficients > 0.25 (Supporting Table 1 [see online supporting information]). Because the index lesion size is subject to interobserver variability, we elected to enter PSA into multivariate models. PSAD was highly collinear with PSA and prostate volume, and with the entry of PSAD, PSA, and prostate volume into multivariate models, PSAD was always selected out, regardless of whether a continuous or categorical variable for PSAD was used. Thus, using PSA and prostate volume as separate covariates resulted in higher predictive accuracies. Race was not included in the multivariate model development because 21 patients declined to report race. Data were incomplete for the index tumor location (anterior/ posterior), so this covariate was not included in the multivariate models. Thus, the final multivariate models incorporated age, PSA, prostate volume, and PI-RADS score (Table 2) . Upon internal validation, the URMC 345 and UAB 345 models performed with AUCs of 0.858 and 0.794, respectively. Upon external validation, URMC 345 and UAB 345 performed with AUCs of 0.795 and 0.845, respectively. The final model for clinical use (URMC1UAB 345), which was based on the combined data sets from both institutions, discriminated with an AUC of 0.825 on internal validation (Table 3) .
The URMC1UAB 345 nomogram demonstrated excellent calibration and a high net benefit in a decision curve analysis (Fig. 1) . A graphical representation of the nomogram is shown and can be used to calculate the probability of having a benign pathology after FB (Fig. 2) . Below a threshold probability of 0.7, a gradual rise in PCa with a GS 3 1 4 was observed (Fig. 3) . Various theoretical predicted probability cutoffs may be considered to 
DISCUSSION
Because FB is becoming rapidly incorporated into contemporary urological practice, 3 an increasing number of patients will undergo biopsies that result in benign pathology. Among patients with a prior negative biopsy who then underwent FB for abnormal mpMRI findings, we found that 132 of 285 patients (46.3%) had benign pathology. Although some cases may represent falsenegative results (eg, TB failures or small foci of disease not well visualized on MRI or not sampled even with the combination of SB and subsequent FB) because of the inherent limitations of mpMRI and FB, 15, 18 some of these patients may indeed have had no cancer. Thus, efforts can still be aimed at reducing the number of unnecessary biopsies with the use of nomograms and predictive models before repeat biopsy sessions. In the current study, we created and validated a nomogram that can be used to predict the probability of having negative FB findings with an AUC of 0.825 at 2 tertiary care centers offering MR/US fusion-guided biopsy. In contrast to biopsying all patients with a prior negative biopsy and a PI-RADS score of 3 to 5 (which is commonly practiced), the URMC1UAB 345 nomogram can provide more individualized decision making for patients in the setting of abnormal mpMRI findings.
Previously, some authors have suggested using the MRI-calculated PSAD in combination with the PI-RADS score for selecting patients for biopsy. 19 In agreement with these results, we found that PSAD was a significant predictor of benign pathology. During model development, PSAD (as either a continuous or categorical variable) was always removed from multivariate models in which PSA and prostate volume were included. Thus, instead of including PSAD in our nomogram, we incorporated PSA and prostate volume as separate covariates. Although the number of prior negative SB sessions intuitively might predict pathology results, we did not find that this covariate was predictive of MR/US FB outcomes, and this is consistent with prior reports. 20 The observation that the number of repeated biopsies does not predict the ability of FB to detect PCa could be related to the unique ability of FB to sample PCa in difficult-to-reach anterior and apical regions of the prostate, which are typically occult during systematic TRUS biopsy sampling alone. [21] [22] [23] We found that performing FB in all patients with a PI-RADS score of 3 to 5 could result in unnecessary biopsying in up to 46.3% of patients. Thus, the use of the URMC1UAB 345 nomogram may minimize unnecessary FB in patients if it is used to aid with clinical decision making. Because of the excellent calibration observed with our nomogram, the predicted probability calculated with this nomogram reflects the patient's actual probability of having benign pathology after FB, and this is useful for counseling patients before a repeat biopsy session is pursued. A theoretical predicted probability cutoff of 0.4 for recommending FB deferment would have prevented unnecessary biopsy in 36.5% of patients and would have missed PCa with a GS 3 1 4 in 6.3% of patients (Fig. 3) . If missing PCa is less tolerable to the patient and the clinician in a shared decision-making model, a higher predicted probability threshold may be used to defer FB. For instance, a cutoff of 0.7 would have prevented unnecessary biopsy in 21.4% of patients and would have missed PCa with a GS 3 1 4 in only 1.4% of patients. If desired, ancillary tests such as the prostate cancer antigen 3 test, prostate health index, 4Kscore test, and ConfirmMDx may also be considered to provide further reassurance about omitting prostate biopsy.
The rationale for combining multi-institutional data sets is the incorporation of a larger data set with multiple institutional variations in patient characteristics, practice patterns, and MRI acquisition and interpretation to maximize nomogram generalizability. Our multi-institutional nomogram incorporates age, PSA, MRI-derived prostate volume, and PI-RADS score for maximum predictive accuracy. Hauth et al 24 recommended follow-up imaging for lesions with a PI-RADS score of 3 because the cancer detection rate for a PI-RADS score of 3 was only 4% in their series. In a prospective study of 62 patients using PI-RADS version 2, 0% of patients with a PI-RADS score of 3 had clinically significant cancer found. 6 Not surprisingly, we found that a PI-RADS score of 3 was a strong predictor of benign pathology, and thus most of these patients may avoid an unnecessary biopsy. Because clinically significant PCa is detected at a higher rate in lesions with PI-RADS scores of 4 and 5 versus 3, performing biopsy for all patients with PI-RADS scores of 4 or 5 may be a reasonable approach. However, under the current PI-RADS version 2 system, mpMRI grading is still subject to a high false-positive rate. 6 A recent, large, prospective evaluation of PI-RADS version 2 demonstrated that cancer detection rates with PI-RADS scores of 3, 4, and 5 were 24.8%, 39.1%, and 86.9%, respectively; this suggested that the majority of those with a PI-RADS score of 4 will not have cancer found after MR/US FB. 25 Although a lesion with a PI-RADS score of 5 should certainly be biopsied, our nomogram can enhance the ability to predict benign pathology and prevent unnecessary biopsies not only for lesions with a PI-RADS score of 3 but also for lesions with a PI-RADS score of 4. The use of the URMC1UAB 345 nomogram has the potential to significantly reduce health care costs and the morbidity associated with unnecessary prostate biopsies, even in the setting of positive mpMRI findings. The URMC1UAB 345 nomogram represents an additional clinical tool for informing patients about the need for repeat prostate biopsy. A limited number of cost-effective analyses evaluating FB have been previously performed. 26 FB is most cost effective when it accurately identifies clinically significant PCa that otherwise is missed on SB. 27 However, because many men will continue to have no PCa found after FB, our nomogram has the potential to spare these men the morbidity of unnecessary biopsies and to reduce health care costs. In a cost-effectiveness analysis by de Rooij et al, 28 the cost of MRI/US FB was comparable to the cost of SB, but FB led to an improvement in quality of life in comparison with SB because of the reduction of overdiagnosis and subsequent treatment. A refinement of indications for FB could further improve quality of life and reduce health care costs, particularly because this technology is rapidly being adopted. Because not all men will have cancer found even in the setting of suspicious mpMRI findings, the clinical impact of false-positive mpMRI examinations warrants further investigation.
To our knowledge, this is the first study to develop a nomogram for predicting benign pathology on FB after a prior negative biopsy. A major strength of our study is that we used benign histology as a clinical outcome rather than a GS 3 1 4, which has been used in other studies. 29, 30 Because patients with a GS of 3 1 3 may be undergraded and undersampled after FB, the use of a GS 3 1 4 as an outcome may result in grouping contamination. The use of benign histology as the primary outcome reduces contamination because patients with no cancer found on TB1SB are much less likely to have clinically significant occult PCa in comparison with patients with a GS of 3 1 3. A known challenge of nomogram development is that accuracy tends to decrease with external validation, particularly for nomograms derived from single-institution databases. A strength of this study is the use of a multi-institutional data set for nomogram development, which allows greater generalizability. 31 Finally, our nomogram demonstrated calibration curves with little deviation from ideal predictions and a high net benefit in a decision curve analysis.
A limitation of this study is that the nomogram was validated only within academic centers with prostate mpMRI expertise and practitioners trained in MR/US FB techniques. Because the performance of mpMRI relies heavily on the availability of high-quality mpMRI acquisition and interpretation, 7 it is unclear whether this nomogram will validate well in clinical centers with less mpMRI experience, those that use different segmentation/ targeting software, or those that do not use standardized PI-RADS scoring. We recommend that before clinical use of this nomogram, each institution should consider retrospectively validating this nomogram's performance in its own cohort of patients with a prior negative biopsy to ensure that institution-specific variations in the patient population and the mpMRI technique do not adversely affect the nomogram's performance. In addition, developing a study consortium involving multiple centers to further validate this nomogram would be of interest and may help to determine whether this nomogram should be widely adopted into clinical practice or incorporated into future clinical guidelines.
In conclusion, among patients with prior negative SB findings, not all patients with abnormal mpMRI findings (ie, a PI-RADS score of 3-5) will have cancer found on subsequent MR/US FB. In this multi-institutional study, we developed and validated the URMC1UAB 345 nomogram for predicting benign pathology after MR/US TB with concurrent SB.
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